meglitinide

01/01/2007 - "These two meglitinide derivatives, commonly called glinides, have been developed for improving insulin secretion of patients with type 2 diabetes mellitus. "
01/01/2003 - "Pharmacology of the meglitinide analogs: new treatment options for type 2 diabetes mellitus."
10/01/2022 - "Nateglinide is a meglitinide used for the treatment of type 2 diabetes mellitus. "
08/02/2010 - "The efficacy and safety of adding meglitinide to metformin monotherapy in patients with type 2 diabetes are unknown. "
09/01/2006 - "Our results provide new insights into the mechanisms of action of GLP-1, and further highlight the promise of GLP-1 or similarly acting analogues alone or in combination with sulphonylureas or meglitinide drugs in type 2 diabetes therapy."

06/01/2003 - "In 1995, several new molecules under study as potential insulinotropic agents for the treatment of non-insulindependent diabetes mellitus were identified as analogs of meglitinide, previously known as the non-sulfonylurea moiety of glibenclamide. "
01/01/2012 - "Many of the therapeutic agents used to treat diabetes mellitus have the ability to lower blood glucose to dangerous concentrations; these include the sulfonylurea, meglitinide, and thiazolidinedione drug classes. "
12/01/2022 - "The conventional medicines for diabetes mellitus include sulfonylureas, biguanide, thiazolidinediones, alpha-glucosidase inhibitors, and meglitinide. "

08/01/2017 - "To clarify four classes of OHAs (sulfonylurea, α-glucosidase inhibitors, meglitinide, and thiazolidinedione) are used in Taiwan for uremia patient with type 2 DM, and in our study, there were no significant differences in survival prognosis for the four drugs. "

01/01/2021 - "Iatrogenic hypoglycemia was defined as a BG measurement less than or equal to 70 mg/dL occurring within the pharmacologic duration of action of administered insulin, sulfonylurea, or meglitinide. "
09/29/2017 - "Meglitinide combined with insulin will increase hypoglycemia in patients with advanced CKD."
04/01/1983 - "The secretion of PP was stimulated by HB 699 before the onset of hypoglycemia, whereas, following glipizide administration, PP secretion increased only after the onset of hypoglycemia. "
01/01/2020 - "Hypoglycemia is a common and sometimes life-threatening adverse event associated with insulin, sulfonylurea, and meglitinide therapies. "
05/01/2010 - "Hypoglycemia often occurs with insulin, sulfonylureas, or meglitinide therapy. "

01/01/2017 - "DPP4is as a third-line add-on to metformin and sulphonylurea combined dual therapy had a significantly lower risk for stroke [HR 0.826 (0.740, 0.923)] and all-cause mortality [HR 0.784 (0.701, 0.878)] than those for acarbose, and significantly lower risks for stroke [HR 0.653 (0.542, 0.786)], heart failure [HR 0.721 (0.568, 0.917)] and all-cause mortality [HR 0.689 (0.594, 0.703)] than those for meglitinide. "
01/01/2016 - "After adjustment of age, sex, hypertension, hyperlipidemia, and antidiabetes agent use (including sulfonylureas, α-glucosidase, metformin, meglitinide, thiazolidinediones, and insulin), TCM cohorts were found to have a 33% decreased risk of stroke (95% CI = 0.46-0.97; P < 0.05).This population-based retrospective study showed that the complementary TCM therapy might associate with the decreased risk of stroke in T2DM, suggesting TCM as an adjunctive therapy for T2DM to prevent subsequent stroke. "
01/01/2017 - "Peer-reviewed articles were identified from MEDLINE and Current Content databases (both 1966 to 1 October 2016) using the search terms insulin, metformin, rosiglitazone, pioglitazone, glyburide, glipizide, glimepiride, acarbose, miglitol, albiglutide, exenatide, liraglutide, lixisenatide, dulaglutide, pramlintide, meglitinide, alogliptin, linagliptin, saxagliptin, sitagliptin, canagliflozin, dapagliflozin, empagliflozin, colesevalam, bromocriptine, mortality, myocardial infarction (MI), heart failure (HF), and stroke. "